Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma Meeting Abstract
| Authors: | Amaria, R. N.; Postow, M. A.; Tetzlaff, M. T.; Ross, M. I.; Glitza, I. C.; McQuade, J. L.; Wong, M. K. K.; Gershenwald, J. E.; Goepfert, R.; Keung, E. Z. Y.; Fisher, S. B.; Milton, D. R.; Patel, S. P.; Diab, A.; Simpson, L.; Davies, M. A.; Wargo, J. A.; Burton, E. M.; Ariyan, C. E.; Tawbi, H. A. H. |
| Abstract Title: | Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120605106 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.9502 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9502 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
